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Abstract: Autologous hematopoietic stem cells transplantation (AHSCT) has been employed as
treatment for severe systemic sclerosis (SSc) with high risk of organ failure. In the last 25 years overall
survival and treatment-related mortality have improved, in accordance with a better patient selection
and mobilization and conditioning protocols. This review analyzes the evidence from the last 5 years
for AHSCT-treated SSc patients, considering in particular the outcomes related to interstitial lung
disease. There are increasing data supporting the use of AHSCT in selected patients with rapidly
progressive SSc. However, some unmet needs remain, such as an accurate patient selection, pretransplantation analysis to identify subclinical conditions precluding the transplantation, and the
alternatives for post-transplant ILD recurrence.
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1. Introduction

Academic Editor: Anna

Systemic sclerosis (SSc) is a heterogeneous, systemic autoimmune disease characterized by small vessel vasculopathy, autoantibodies production, and fibroblast activation
leading to fibrosis of the skin and internal organs [1]. The clinical manifestations and the
prognosis of SSc are variable: the majority of patients have skin thickening and variable
involvement of internal organs. Among the different forms of SSc, classified according to
the extent of skin thickening [2], patients with the diffuse form (dcSSc) show earlier and
more frequent organ involvement [3]. The most relevant complications for SSc are related
to pulmonary involvement and these are the direct expression of the pathogenic features of
the disease: pulmonary arterial hypertension (PAH), as the most aggressive manifestation
of vascular damage, and interstitial lung disease (ILD), as the most life-threatening manifestation of the fibrotic process of SSc [4]. Among these, SSc-associated interstitial lung
disease (SSc-ILD) represents the leading cause of mortality in patients with SSc with 3-year
survival of only 52% [5]. The clinical course of SSc-ILD is variable: some patients show
stable or improving forced vital capacity (FVC) while others show a progressive decline in
lung function [6], that occurs more rapidly within the first few years after diagnosis and
then in some cases slows down. The clinical heterogeneity of the disease in association with
the poor survival rate makes clinical trial enrichment difficult and complicates stratification
and therapeutic management [7].
Over the past 20 years, cyclophosphamide (CYC) has been considered the standard
of care for SSc with early aggressive skin disease and concomitant progressive ILD [8,9],
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and more recently, mycophenolate mofetil (MMF) has been added to the therapeutic
options for the management of SSc-ILD, after the results of the Scleroderma Lung Study
II [10]. In addition, the most recent recommendations of the panel of experts support
the use of hematopoietic stem cell transplantation (HSCT) in SSc patients with rapidly
progressive disease and high risk of organ failure based on two randomized clinical trials
(RCTs) that evaluated the efficacy and safety of high-dose immunosuppressive therapy
with subsequent HSCT [11,12]. Indeed, these trials showed that HSCT improves eventfree survival compared to CYC, an endpoint that is not reached by any pharmacological
treatment to date. Nonetheless, the clinical decision to address SSc patients to HSCT is
further complicated by the identification of essential requirements: knowing with a degree
of certainty that the disease is rapidly progressive, which depends also on the medications
currently used by the patient; convincing the patient, which might be challenging since
these are SSc patients at high risk of organ failure that do not realize the actual risk of their
disease; assessing that the disease is progressing in a monotonic fashion without chances to
slow down spontaneously to identify the appropriate timing.
As a form of intensive immunotherapy that targets the autoreactive adaptive immune system, HSCT deeply modifies the immune system, restoring the immunological
balance that counteracts inflammation and fibrosis progression, enabling disease control and, eventually, tissue repair [13]. Briefly, HSCT consists of four steps: mobilization of hematopoietic stem cells using chemotherapy, such as CYC, and growth factors
[granulocyte colony-stimulating factor (G-CSF)]; conditioning using myeloablative or nonmyeloablative regimens to eradicate autoreactive immune cells; reinfusion of autologous
stem cells and immune reconstitution [14]. In contrast to myeloablative stem cell transplant,
non-myeloablative transplant differs primarily in what happens prior to the transplant,
since it employs much lower and less toxic doses of chemotherapy. Different combinations
of mobilization and conditioning regimens have been used in randomized clinical trials
in SSc-ILD.
The aim of the present review is to analyze the evidence from observational and
retrospective studies and RCTs regarding autologous hematopoietic stem cells transplantation (AHSCT) in SSc-ILD published between January 2016 and December 2021. Studies
involving less than 10 patients were excluded, as well as study designs, animal studies, case
reports, review articles, letters to the editor, conference abstracts, editorials, and guidelines.
2. HSCT and SSc-ILD
2.1. Efficacy of HSCT in SSc-ILD
2.1.1. Randomized Clinical Trials
Two randomized controlled trials, ASSIST (American Scleroderma Stem cell versus
Immune Suppression Trial) in 2011 and ASTIS (Autologous Stem cell Transplantation International Scleroderma trial) in 2014 [12], both using non-myeloablative regimen, demonstrated the superiority of AHSCT compared to CYC. In these two trials the conditioning
phase consisted of a non-myeloablative regimen with CYC (200 mg/kg total dose) and
rabbit antithymocyte globulin (rATG). The main differences were the CYC dose, and the
selection of peripheral blood stem cells used for the mobilization phase.
In the ASSIST trial, 2 g/m2 CYC was administered, and unmanipulated peripheral
blood stem cells were infused, while in the ASTIS trial stem cells were mobilized with
4 g/m2 CYC and CD34+ selected peripheral blood stem cells were infused. Both trials
used similar inclusion criteria (patients age between 18 and 65 years, with dcSSc and a
maximum disease duration of 4 years, minimum modified Rodnan skin score (mRSS)
of 15 and involvement of heart, lungs, or kidney). The ASSIST trial showed that nonmyeloablative AHSCT improves skin and pulmonary function for up to 2 years. In the
ASTIS trial the superiority of AHSCT vs. CYC was confirmed. Despite the occurrence of
early treatment-related mortality during the first year after AHSCT (16.5%), and an increase
in serious adverse events, especially characterized by respiratory and cardiac failure, the
use of AHSCT was associated with increased long-term event-free survival [12].
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In 2018 an additional randomized clinical trial, the Scleroderma: Cyclophosphamide or
Transplantation trial (SCOT) was published. In this trial similar inclusion criteria were used,
with GCS-F for mobilization and with CD34+ selected cells. The myeloablative regimen
employed conditioning using a lower dose of CYC (120 mg/kg total dose) plus total body
irradiation (TBI) (800 cGy/4 fractions over 2 days/200 cGy to lungs and kidneys with
shielding) and equine ATG [15]. The trial enrolled 75 patients with severe SSc. Thirty-four
were assigned to HSCT and 39 to CYC, ending at month 54, with a maximum follow-up to
72 months. One of the main differences, in comparison to previous RCTs, is the selection
of the primary endpoint. This was identified in the global rank composite score (GRCS),
an analytic tool which includes multiple disease features, including death and event-free
survival, FVC, the Disability Index of the Health Assessment Questionnaire (HAQ-DI)
score, and the mRSS. After 54 months, a large percentage (67%) of patients, treated with
HSCT, reached the primary endpoint, the improvement of GRCS when compared with
CYC arm (33%). Of note, the exclusion criteria were rigorous. These included active gastric
antral vascular ectasia, a diffusing capacity of the lung for carbon monoxide (DLco) of less
than 40% of the predicted value, an FVC of less than 45% of the predicted value, a left
ventricular ejection fraction of less than 50%, a creatinine clearance of less than 40 mL per
minute, pulmonary arterial hypertension, or more than 6 months of previous treatment
with CYC. Treatment-related mortality, in the transplantation group, was 3% at 54 months
and 6% at 72 months, when compared with 0% in the CYC group. However, transplantrelated mortality was lower than previous reports, but the reason is still unknown, and it
might be partly explained by the differences in inclusion criteria (in the SCOT trial none
of the patients had cardiac involvement) and in conditioning regimens (in the ASTIS trial
high-dose regimen of CYC may has been toxic, especially in the presence of heart disease).
Notably, in this trial, treatment of severe scleroderma with myeloablative therapy
and CD34+ selected autologous hematopoietic stem-cell transplantation led to superior
long-term outcomes as compared with standard therapy and fewer scleroderma relapses,
defined as the need for disease-modifying antirheumatic drugs (DMARD) therapy after
non-myeloablative regimen, probably due to T cell depletion after total body irradiation.
However, the adverse events occurring in the first 2 years after transplantation, such
as viral infections and secondary cancers due to total body irradiation exposure, were
relevant (96% in the transplant group vs. 71% in the CYC group). Cancers occurred in four
participants: three in the transplantation group (one had papillary thyroid cancer and two
had the myelodysplastic syndrome) and one in the CYC group (breast cancer). A total of
21 deaths occurred over a period of 72 months in this trial, 14 in the CYC group and 7 in
the transplant group.
2.1.2. Prospective and Cross-Sectional Studies
Prospective studies in the last 5 years have shown that AHSCT in systemic sclerosis
resulted in long-term improvements in skin thickness and pulmonary function, but its
efficacy may be limited by the relatively high treatment-related mortality, and morbidity.
Patients with dcSSc for less than 2 years, without severe cardiac and renal involvement,
without pulmonary hypertension, exposed to non-myeloablative conditioning regimen
with high-dose of CYC and CD34+ selected cells, benefit from AHSCT with improvement
in skin thickness and improvement or stability of pulmonary function [14–17]. A post hoc
analysis of a phase I/II clinical trial conducted in Japan compared the efficacy and safety
of CD34-selected auto-HSCT in comparison to unmanipulated auto-HSCT. The authors
observed that FVC improved continuously for 8 years in patients that underwent CD-34
selection before transplant, while in the unmanipulated group FVC returned to baseline
after 3 years. This was accompanied by an increase in toxicity and in viral infections rate in
the CD-34-selected group without differences in serious adverse events or death [16]. In
addition, a large multicenter non-interventional study analyzed real-life efficacy of AHSCT
including 80 SSc patients using as primary endpoint progression-free survival (PFS), defined
as survival after AHSCT without death or evidence of progression of SSc [15]. While, in
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this study, the mobilization regimen was similar across the centers (CYC 1–4 g/m2 ) and
the conditioning process was not based on myeloablative approaches, the main difference
in terms of efficacy was observed in those exposed to CD-34 selection with a better clinical
response. Interestingly, long term data from a Japanese phase II trial, with a median
follow-up period of 137 months involving 14 patients, confirmed a high overall survival
(93%) and a stable pulmonary function in 85% of the subjects treated with HSCT [16].
Several authors have studied patient serum cytokine profiles before and after AHSCT to
assess whether immune monitoring can be useful in predicting clinical response [17–19] A
modified immune response is essential to SSc physiopathology, and an alteration in the
cytokines and growth factors seems to precede tissue fibrosis. High levels of IL-2, IL-6, IL-8,
MCP-1, and IFN-γ reported in SSc patients before AHSCT confirm the pro-inflammatory
features of the disease. After AHSCT, authors observed a significant reduction in IL-2 and
IL-8 levels, and a slight but significant decrease in TGF-β which may reflect a decrease of
SSc fibroblast activation after AHSCT in dcSSc subjects. Monocyte chemoattractant protein
1 (MCP-1) also participates to fibrosis via different mechanisms, comprising augmented
fibroblast growth and collagen production, and MCP-1 amounts decreased after transplant
with progressive reduction over the 48 months after transplant. Finally, platelet derived
growth factor (PDGF) is linked to fibrosis, and although the study found no augmentation
in circulating levels of PDGF before transplant, a significant reduction at 6 months after
AHSCT was reported [20], (Table 1).
Clinical improvement of SSc patients may be related to increased counts of newly
generated Tregs and B regs after AHSCT as a result of coordinated thymic and bone
marrow rebound [18]. High PD-1 expression is associated with better clinical outcomes
after AHSCT [17]. Antibody reactivity towards topoisomerase-I decreases after HSCT and
correlates with good clinical response while the reactivity to the epitope anti-topo489–573
was significantly higher in SSc patients that did not respond to AHSCT as compared with
subjects with a good response [19].
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Table 1. Prospective studies.
SCOT Trial
[15]

Ayano, M., et al.
[21]

Helbig, G., et al.
[22]

Henes, J., et al.
[23]

Nakamura, H., et al.
[16]

Farge, D., et al.
[24]

Michel, L., et al.
[20]

Arruda, L., et al.
[17]

Total: 80

Total: 14

Total: 10

Total: 38

Total: 31

<3

<2

<2

<2

Participants

Total: 65
HSCT: 33
CYC: 32

Total: 19
CD34+: 11
CD34−: 8

Total: 18
CYC + alemtuzumab: 11
Melphalan +
alemtuzumab: 2
CYC and rATG: 4
CYC alone: 1

Disease
duration (years)

<4

<4

<10

<2

Age

18–69

16–65

18–70

18–65

16–60

18–65

18–65

19–58

PFTs

FVC: 45–70
DLco: 45–70

FVC: <70
DLco: <70

FVC: 40–80
DLco: 40–80

FVC: >40
DLco: >40

FVC: >45
DLco: >45

FVC: >50
DLco: >45

FVC: <70
DLco: 45–70

FVC: >45
DLco: >45

mRSS

>15

>15

>15

>15

>15

>15

>20

>14

Heart
involvement

no

no

no

no

no

no

no

no

Follow-up (months)

54

96

42

24

144

104

48

36

Mobilization

G-CSF

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

Conditioning

TBI 800 cGy + CYC
120 mg/kg + eATG
90 mg/kg vs. CYC
750 mg/mq

CYC (50 mg/kg)

CYC 200 mg/kg +
alemtuzumab 60 mg, or
melphalan 140 mg/mq +
alemtuzumab, or CYC +
rATG 7.5 mg/kg, or CYC

CYC 200 mg/kg

CYC 200 mg/kg

CYC 50 mg/kg +
ATG

CYC 50 mg/kg +
ATG

Cy 200 mg/kg +
4.5 mg/kg ATG

CD-34 selection

yes

yes
(11 patients)

no

yes
(35 patients)

yes
(5 patients)

yes
(5 patients)

yes

no

Event-free survival
(EFS) or
Progression-free
survival (PFS)

EFS: 74% in HSCT vs.
47% in CYC at
6 years

PFS: 51.3%

PFS: 33%

PFS: 81.8%

40% at 10 years

-

-

-

Overall survival

86% in HSCT vs. 51%
in CYC at 6 years

79%

61%

90%

93% at 10 years

-

-

97%

Transplant-related
mortality

3%

zero

24% (protocol
amendment for
alemtuzumab)

6%

7.1%

-

-

-

Pulmonary function
outcomes

HSCT superior

FVC improved at
8 yearsDLco stable

FVC and DLco stable at
12 months

FVC
improved-DLco
stable

85% stable at
12 months

-

-

-
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2.1.3. Retrospective Studies
In a retrospective study 41 SSc patients undergoing HSCT were compared with 65 SSc
patients treated with conventional care. Patients fulfilled the HSCT eligibility criteria of
the ASTIS trial (age > 18 years, dcSSc, maximum disease duration of 4 years, minimum
mRSS of 15, lung, heart, and renal involvement). The HSCT resulted in a reduction of the
mRSS and a stability of the DLco. Pre-transplant cardiac screening is therefore essential not
only for risk assessment during the treatment but also to anticipate response [25]. Longterm retrospective analysis of HSCT among all patients treated with HSCT for SSc in the
Netherlands until 2017 (n = 92) gave estimates of event-free survival at 5, 10, and 15 years
as 78%, 76%, and 66%, respectively. In this cohort, FVC increased during follow-up from
84% to 94% at 5 years of follow-up, while DLco increased from 55% to 61% at 5 years, which
is significant but not clinically meaningful [26]. Similarly, Del Papa et al. demonstrated,
in a head-to head comparison between HSCT and CYC study, that both FVC and DLco
remain unchanged after AHSCT [27]. Indeed, other retrospective studies confirm that both
Dlco and FVC improve after HSCT [25,28]. Furthermore, an improvement of clinical scores
within the first year after transplant is a predictor for long-term clinical responses [24],
(Table 2).
Table 2. Retrospective studies.
Gernert, M., et al. [29]

Van Bijnen, S., et al. [26]

Del Papa, N., et al. [27]

Henrique-Neto et al. [28]

Participants

17

89

Total: 54
HSCT: 18
Standard care: 36

70

Disease duration (years)

<4

1.5 (median)

<4

Up to 7 years

Age

23–64

46 (median)

20–64

19–59

PFTs

FVC >58
DLco: >30

FVC: 85 (median)
DLco: 45 (median)

FVC > 50
DLco > 50

FVC < 45%
DLco > 40%

mRSS

>20

>14

>14

>14

Heart involvement

yes

yes

no

-

Follow-up (months)

12

60

60

60

Mobilization

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

G-CSF + CYC

Conditioning

CYC 200 mg/kg +
ATG 30 mg/kg

CYC (50 mg/kg) +
rATG 2.5 mg/kg +
methylprednisolone
1 mg/kg

CYC 200 mg/kg +
rATG 7.5 mg/kg

CYC 200 mg/kg + ATG
4.5 mg/kg (for patients
with heart involvement:
fludarabine 120 mg/m2 +
melphalan 120 mg/m2 +
4.5 mg/kg ATG

CD-34 selection

yes

yes

yes

no

Event-free survival (EFS) or
Progression-free survival
(PFS)

-

EFS: 78% at 5 years

-

PFS: 70.5% at 8 years

Overall survival

-

77% at 55 months

89% in SHCT vs. 39% in
CYC at 5 years

81% at 8 years

Transplant-related mortality

5.9%

11%

5.6%

4%

Pulmonary function
outcomes

-

FVC and DLco improved
at 5 years

Stabilization of FVC and
DLCO in HSCT. No
difference between HSCT
and CYC

FVC and DLco stable at
5 years

2.2. HSCT Safety and Complications in SSc-ILD
A crucial point for AHSCT in systemic sclerosis is safety. The risk of early transplantrelated complications and mortality varies according to the type of disease, pre-existing
internal organ involvement, the experience of the transplant center, and the intensity of the
conditioning regimen [30]. Major adverse events and treatment-related mortality (TRM)
after HSCT are predominantly related to primary cardiac and lung involvement [11,12,15].
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They represent the leading cause of mortality after AHSCT for autoimmune disease and
cluster within the first month after AHSCT. While in the ASTIS trial, viral infections were
detected in 27.8% of patients in the group of SSc patients treated with AHSTC group
versus 1.3% in the control arm, overall infection rates were similar in the two treatment
arms of the SCOT trial except for varicella zoster infection that was detected in 36% of
AHSCT treated patients. TBI used in myeloablative conditioning regimen is more lethal for
hematopoietic stem cells. It is responsible for the hematological neoplasms, as observed
in the comparison between ASTIS and SCOT trials and might account for the cardiopulmonary deaths as observed in patients undergoing myeloablative regimen [15,16,31–33].
High-dose cyclophosphamide, however, included in myeloablative conditioning regimens,
is also toxic for the heart function, leading to life-threatening myocardial hemorrhage,
fatal cardiomyopathy, and heart failure [34]. The specific effect of TBI and CYC on cardiac function needs to be better clarified to assess the contribution of each component to
treatment-related outcomes. Based on the results presented by Helbig G. et al. [22], the use
of alemtuzumab, in association with CYC, for the conditioning phase, was associated with
an increased occurrence of infections and thus it should be avoided because of high risk of
developing infectious complications. Indeed, one of the main clinical unmet needs is the
identification of the most effective conditioning protocol avoiding the toxicity induced by
over-treatment and the concomitant increase in infection rate. The ASTIS trial showed that
the administration of CYC at 200 mg/kg body weight with rATG 7.5 mg/kg body weight
seems to be the best protocol [12].
Many factors influence the outcome of transplant, and they are as follows: HSCT protocol, age of patient, disease duration before transplant, quality of life, and co-morbidities,
e.g., decreased left ventricle ejection fraction (LVEF) or pulmonary arterial hypertension
(PAH). The most frequent complications are viral reactivations (CMV, EBV, HSV) and
opportunistic infections [21,22,27,29]. Reactivation may be dependent on ATG in conditioning [29] and occurs more frequently in CD34-selected patients [21] and in patients
with low B cell count prior to transplant [29]. Determination of the CMV and the EBV
serostatus before HSCT seems advisable to identify patients at risk for virus reactivations
and prophylaxis may be useful in patients with positive serology. HSCT allows patients
with refractory autoimmune disease during childbearing years the opportunity to conceive
during treatment-free remissions with favorable pregnancy outcomes and reduces the risks
of maternal complications of the underlying disease [35].
2.3. SSc-ILD Patients Selection for HSCT
Cardiac dysfunctions that occur during transplantation accounted for many of the
transplant-related deaths described in several studies [15,16,23,26]. Male sex, older age,
and LVEF < 50% are independently associated with events [26], as is smoking as reported in
the ASTIS and SCOT trials [12,15]. A relevant decrease of mortality rate could be achieved
with a more accurate selection of candidate patients and a better pre-transplant definition
of cardio-pulmonary risk. Cardiac evaluation before use of mobilization and conditioning
regimen includes electrocardiogram and echocardiography with pulmonary artery pressure
to exclude patients with pulmonary arterial hypertension [30]. However, the screening of
cardiac function using only electrocardiogram and echocardiography remains insufficient
in diagnosing occult heart disease [36]. Since 2012 this evaluation was extended with left
and right heart catheterization including fluid challenge, 24 h Holter registration if history
of palpitations or abnormal ECG, and cardiac MRI when indicated [37].
3. Discussion
In this review we summarized the results of studies of the last 5 years employing
AHSCT for the treatment of SSc patients at high risk of organ failure. AHSCT ameliorates
skin involvement and improves or stabilizes lung function, especially in patients with
disease duration of less than five years [13,38]. The patient-related perspective confirms that
this procedure is well-tolerated and improves quality of life, as shown by a recent systematic
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review [39]. Robust evidence for the efficacy of AHSCT in SSc-ILD is, however, still lacking
because HSCT trials and studies have differences in inclusion criteria, treatment regimens,
and clinical endpoints and a comparison between them remains difficult. Although this
procedure maintains a 5–15% risk of mortality, it induces, in the great majority of treated
patients, improvement in survival, disease activity and skin thickening, and, eventually, a
stabilization of lung function. However, it is unclear how far forward AHSCT should be
positioned as an upfront therapy vs. its role as a rescue treatment for patients’ refractory to
immunosuppressive therapy. As immunosuppressive and antifibrotic therapies advance in
efficacy and specificity, the opportunities to apply AHSCT as a rescue therapy recede but as
its safety improves, the opportunities to use AHSCT earlier increase. Overall, early toxicity
remains the principal challenge. In particular, a more individualized regimen with respect
to heart, lung or kidney involvement might further improve patients’ safety by reducing
toxicity and treatment-related mortality of the conditioning phase.
Many centers select the cells infused into the patients by removing T cells and concentrating CD34+ cells. This approach has controversial results and thus the benefits of ex vivo
CD34+ positive selection of the graft remains debated. A potential beneficial effect might be
the preliminary elimination of auto-reactive cells, even if a recent multicenter retrospective
study demonstrated that the use of selected CD34+ cells in SSc confers no benefit over
unselected cells [40]. CD34+ selection may delay T cell reconstitution for the first 8 months
after transplant [41] and remove auto-reactive cells and also regulatory T-cells. Indeed,
post-transplant CD4 T-cell reconstitution correlates with long-term clinical response posttransplant [17]. Further studies are still required to explore the benefits of CD34+ selection.
On the other hand, changes in the conditioning regimen among the trials provided different
results in terms of efficacy and safety. The SCOT trial, employing low dose CYC and TBI,
induced three times more malignancies (9%; two cases of myelodysplastic syndrome and
one of medullary thyroid cancer). Indeed, the use of myeloablative conditioning regimen
is the main difference in this trial compared to previous trials and must be accounted for
when comparing the results of these trials. However, the SCOT trial reported an impressive
treatment-related mortality of 3% at 54 months and 6% at 72 months, superior to previous
trials. There are several explanations for these findings: first, the use of lower dose CYC,
has less cardiotoxic effects as reported in the adverse events profile of the SCOT trial.
Furthermore, the exclusion of smokers and patients with cardiac dysfunction in association
with a better cardiac function assessment by using right heart catheterization with fluid
challenge and cardiac magnetic resonance imaging to identify early cardiac involvement
might have reduced the number of SSc at high risk of treatment-related complications.
Although new pharmacological therapies are emerging, international guidelines recommend treating selected patients with early rapidly progressive dcSSc with AHSCT
in highly experienced bone marrow transplant centers. Notably, in recent years new
pharmacological therapies have been tested in phase III randomized clinical trials for
SSc-ILD, increasing the options for the management of this disease. The phase III trials
of nintedanib [42] and tocilizumab [43] for SSc-ILD patients represent an advancement
in the management of SSc-ILD. However, overall survival is not included in the primary
endpoints of these trials and this endpoint is the most relevant aspect when comparing
pharmacological and HSCT trials in SSc. On the other hand, in trials using AHSCT ILD
presence per se is not used as a single inclusion criterion, thus the comparison with pharmacological trials becomes even more problematic [40]. A recent retrospective real-world
study aimed at assessing the evolution of ILD in SSc patients treated with AHSCT and CYC
at 1 year. This study show that 90% of patients treated with HSCT or CYC present stable or
reduced ILD extent assessed by HRCT, although no definitive conclusion can be drawn
for the superior efficacy of one regimen upon the other, possibly due to the relative short
period of observation [41].
The comparison between the SCOT trial and the previous trials, despite having similar
eligibility criteria and control treatment, is limited by the variability of the endpoints. In
the SCOT trial the use of a composite endpoint, the global rank composite score (GRCS),
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provides a systemic view of the disease manifestations and treatment effect. However, this
approach limits the analysis of the results: first, this score has not yet been validated and
thus the individual components require an accurate sub-analysis to identify the withinscore differences. In addition, confirmation of their validity is needed before they can
achieve widespread acceptance and, in the case of SSc trials, they have never been used
and validated. Interestingly, Farge et al. applied the GRCS to the French participants of
the ASTIS trial to compare the efficacy according to the same endpoint used in the SCOT
trial [41], supporting its use to standardize the endpoint for future trials.
This is particularly important when analysing the efficacy of AHSCT in the treatment
of ILD. The comparison between the results of the trials and other retrospective and
prospective studies suggest that a clear definition of the appropriate pulmonary function
tests to use as a marker of disease progression needs to be better clarified and might
be related to baseline characteristics of patients treated with AHSCT [44]. In particular,
DLco does not improve in patients with cardiac involvement before transplant but only in
those with normal cardiac tests at baseline. In fact, longer-term follow-up of pulmonary
function and alterations shows that the effects of AHSCT on the evolution of ILD tend
to decrease over-time and eventually disappear in some patients, returning to the pretransplant conditions two years after AHSCT. For this group of patients, Rituximab, an
anti-cd20 biologic agent, showed a promising profile of safety and efficacy, offering the
opportunity to avoid ILD recurrence or worsening after AHSCT [45]. This directly raises
the question whether future trials should focus on the stabilization of pulmonary function
improvement after AHSCT and to identify SSc patients at risk of long-term ILD progression
or re-activation.
SSc is characterized by auto-antibodies production and T-cell infiltration. The various
cytokines and chemokines produced by the activated T cells recruit additional inflammatory
cells and activate fibroblasts, that in turn promote extracellular matrix production and
excessive fibrosis within the skin and internal organs. The exact mechanism of action of
HSCT remains unknown. Some authors hypothesize that AHSCT resets the immune system
with re-emergence of naive B cells and T cells and progressive increase in the regulatory
T-cell number and in the Th1/Th2 cell ratio [46,47]. This might lead to the occurrence of
secondary autoimmune disorders and engraftment syndrome that is much more frequent
in patients with cardiac involvement, thus further reinforcing the relevance of an accurate
screening of cardiac subclinical alterations and the opportunity to employ less cardiotoxic
approaches, such as fludarabine [48,49].
4. Conclusions
Recent advances in SSc-ILD pathogenesis and emerging phase III clinical trials for new
pharmacologic treatments for the treatment of SSc-ILD show convincing data regarding
stabilization of pulmonary function, but no pharmacological trials have yet achieved
increased overall survival as primary endpoint. The results of recent phase II and phase III
trials, however, warrant a revision of the actual trial designs for AHSCT in order to include
a better definition of the comparator drug. In addition, accumulating evidence from recent
randomized clinical trials employing AHSCT suggest that the combination of a better
cardiac evaluation of SSc patients, in association with CD-34+ selection in the mobilization
phase and a reduced dose of CYC in the conditioning phase, confers a favorable long-term
overall survival with an acceptable safety profile [14]. However, the progression of lung
disease remains an unmet need and requires an accurate stratification of these patients to
assess their eligibility for further pharmacological maintenance therapy with new emerging
SSc-ILD specific drugs.
5. Future Directions
HSCT has been used for more than 20 years as a specific treatment in a wide range of
autoimmune disease [50,51]. The rationale for HSCT is based on its capacity to reset the
immune system after eradication of the autoreactive cells with high immunosuppressive
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or myeloablative conditioning regimen, allowing the reconstitution of immune tolerance.
The UPSIDE trial is ongoing and investigates AHSCT in early disease compared to other
immunosuppressive therapy with the specific aim to treat the immunosuppressive arm with
AHSCT as a rescue therapy if the response is poor [36]. In SSc, the debate on the potential
benefits and risks of transplantation and the correct identification of high-risk subjects
remains difficult and the recent approval of new immunosuppressive and anti-fibrotic
drugs offers the possibility to provide long-term beneficial effects for the management of
ILD both before and after AHSCT [52]. Notwithstanding the new drug approvals and the
ambiguities of protocol in its use, AHSCT remains the only intervention to offer proven
survival benefit in SSc thus far.
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